根治性膀胱切除术后发生异时性上尿路尿路上皮癌的风险适应评分模型的开发与验证
该研究基于两个机构登记库的回顾性数据,在3170例训练队列和959例验证队列的根治性膀胱切除术(RC)患者中开发并验证了异时性上尿路尿路上皮癌(UTUC)的风险评分模型。多变量分析识别出阳性尿路上皮切缘、RC前卡介苗(BCG)治疗史、RC时原位癌和RC前肾积水为独立风险因素,模型在训练和验证队列中C统计量分别为0.71和0.73。风险评分将患者分层为低、中、高风险,5年无UTUC生存率在训练队列分别为99%、96%、89%,验证队列为98%、96%、91%。
要点
- RC后UTUC风险因素包括阳性尿路上皮切缘、BCG治疗史、原位癌和肾积水。
- 风险评分模型在训练和验证队列中表现出良好的区分能力(C统计量0.71和0.73)。
- 评分将患者分为低(0分)、中(1-3分)、高(4+分)风险,5年无UTUC生存率分别为99%、96%、89%(训练队列)。
核心结论
- 开发并验证了RC后UTUC的风险评分,可能优化术后UTUC监测方案。
研究设计与样本
- 回顾性 review 两个机构登记库,训练队列3170例RC患者,验证队列959例RC患者。
主要发现
- 中位随访4.6年(IQR 2.1-8.7),167例诊断为UTUC。
- 多变量分析风险因素:阳性尿路上皮切缘(HR 2.60,p<0.01)、RC前BCG治疗史(HR 2.20,p<0.01)、RC时原位癌(HR 2.01,p<0.01)、RC前肾积水(HR 1.48,p=0.04)。
- 训练和验证队列C统计量分别为0.71和0.73。
- 风险评分分层:低风险(0分)、中风险(1-3分)、高风险(4+分)。
- 5年无UTUC生存率:训练队列低99%、中96%、高89%;验证队列低98%、中96%、高91%。
关键数值与推荐
- 风险评分变量及分值:阳性尿路上皮切缘、RC前BCG治疗史、RC时原位癌、RC前肾积水(具体分值未报告)。
- 风险分层:低风险0分,中风险1-3分,高风险4+分。
- 5年无UTUC生存率:训练队列99%、96%、89%;验证队列98%、96%、91%。
临床怎么用
- 该风险评分可用于RC术后UTUC的风险分层,帮助个体化制定监测方案。
局限性
- 回顾性研究设计。
- 未报告外部验证 beyond 两个机构。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The incidence and risk factors for metachronous upper tract urothelial carcinoma (UTUC) following radical cystectomy (RC) remain incompletely defined, which has limited the ability to individualize postoperative surveillance. MATERIALS AND METHODS: A retrospective review of 2 institutional registries was performed to identify patients undergoing RC for urothelial carcinoma. Multivariable Cox proportional hazard models for metachronous post-RC UTUC were developed in one institutional data set and validated in the second institutional data set. A post-RC UTUC risk score was then developed from these models. RESULTS: A total of 3,170 RC patients were included from the training cohort and 959 RC patients from the validation cohort. At a median followup after RC of 4.6 years (IQR 2.1-8.7), 167 patients were diagnosed with UTUC. On multivariable analysis in the training cohort, risk factors for metachronous UTUC were the presence of positive urothelial margin (HR 2.60, p <0.01), history of bacillus Calmette-Guérin treatment prior to RC (HR 2.20, p <0.01), carcinoma in situ at RC (HR 2.01, p <0.01) and pre-RC hydronephrosis (HR 1.48, p=0.04). These factors had similar discriminative capacity in the training and validation cohorts (C-statistic 0.71 and 0.73, respectively). A UTUC risk score was developed with these variables which stratified patients into low (0 points), intermediate (1-3 points), and high risk (4+ points) for post-RC UTUC, with respective 5-year UTUC-free survivals of 99%, 96%, 89% in the training cohort and 98%, 96%, and 91% in the validation cohort. CONCLUSIONS: We developed and validated a risk score for post-RC UTUC that may optimize UTUC surveillance protocols after RC.
引用
- Miest T, Khanna A, Sharma V, et al. Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy. J Urol. 2021. PMID: 34547921. doi:10.1097/JU.0000000000002211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。